Takeda Pharmaceutical's strong earnings, dividends, and strategic moves make it an appealing investment despite US policy uncertainties. Read my earnings analysis.

Welcome to the AbbVie fourth-quarter 2024 Earnings Conference Call. [Operator instructions] Today's call is also being ...

Meanwhile, a new subcutaneous formulation of Takeda’s Entyvio (vedolizumab) – currently given as an intravenous infusion – was recommended for approval by the EMA as a maintenance therapy in ...

We recently launched Vyalev, the only subcutaneous 24-hour continuous infusion ... a study comparing Skyrizi to Entyvio in ulcerative colitis will be initiated. Additional mid-stage monotherapy ...

Q4 2024 Earnings Call Transcript January 31, 2025 AbbVie Inc. misses on earnings expectations. Reported EPS is $2.16 EPS, expectations were $2.98. Operator: Good morning and thank you for standing by.

It will compete with other biologic therapies for Crohn's, including J&J's IL-12 and IL-23 inhibitor Stelara (ustekinumab), Takeda's Entyvio ... followed by a 360mg subcutaneous shot given ...

The subcutaneous formulation of Opdivo provides a convenient alternative to intravenous administration for patients with solid tumors, maintaining efficacy and safety. The CHECKMATE-67T trial ...

Jeffrey Stewart; Executive Vice President, Chief Commercial Officer; AbbVie Inc Carrie Strom; Senior Vice President, AbbVie and President, Global Allergan Aesthetics; AbbVie Inc Roopal Thakkar; ...

Good morning and thank you for standing by. Welcome to the AbbVie fourth-quarter 2024 Earnings Conference Call. [Operator instructions] Today's call is also being recorded. If you have any ...

AbbVie provided an optimistic outlook for 2025, with an adjusted EPS guidance range of $12.12 to $12.32 and total net revenues expected to reach $59 billion. The company anticipates significant ...

AbbVie's Q4 EPS of $2.16 beat the forecast by $0.10. Revenue for the quarter was $15.1 billion, exceeding expectations. The stock price increased by 6.82% following the earnings release. Full-year ...

With this approval, HYQVIA [Immune Globulin Infusion 10% (human) with Recombinant Human Hyaluronidase] becomes the first and only facilitated subcutaneous immunoglobulin available in Japan to treat ...